US health officials have revoked the authorisation of bevacizumab (Avastin) for breast cancer treatment, saying the drug has "not been shown to be safe and effective for that use".
Bevacizumab will remain on the market as an approved treatment for certain types of colon, lung, kidney and brain cancer, but will no longer be indicated for advanced breast cancer, said the US Food and Drug Administration.
In a statement released by the FDA last week, commissioner Dr Margaret Hamburg said:"FDA recognises how hard it is for patients and their families to cope with metastatic breast cancer and how great a need there is for more effective treatments."
"But patients must have confidence that the drugs they take are both safe and effective for their...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.